IP Library › Granted Patent US 7,759,518
Granted Patent B2
US 7,759,518 · App. 12/323,279 · Granted Jul 20, 2010

Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,759,518
App. No.
12/323,279
Granted
Jul 20, 2010
Kind
B2
Abstract

This invention concerns N-(2-arylamino)aryl sulfonamides, which are inhibitors of MEK and are useful in treatment of cancer and other hyperproliferative diseases.

Claims (4)

1. The compound (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide:

2. A pharmaceutical composition comprising a therapeutically effective amount of (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide:

3. The composition of claim 2 , further comprising a pharmaceutically acceptable carrier.

4. The composition of claim 3 , substantially free of (R)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
CORRECTIVE PARTIAL RELEASE OF SECURITY INTEREST IN PATENTS Recorded Oct 12, 2011
From: GOLDMAN SACHS LENDING PARTNERS LLC
To: VALEANT PHARMACEUTICALS INTERNATIONAL; ATON PHARMA, INC.; CORIA LABORATORIES, LTD.; DOW PHARMACEUTICAL SCIENCES; VALEANT PHARMACEUTICALS NORTH AMERICA LLC,; PRESTWICK PHARMACEUTICALS, INC.; VALEANT BIOMEDICALS, INC.
Reel/Frame 027052/0883 →
SECURITY AGREEMENT Recorded Jul 18, 2011
From: VALEANT PHARMACEUTICALS INTERNATIONAL, A DELAWARE CORPORATION; ATON PHARMA, INC., A DELAWARE CORPORATION; CORIA LABORATORIES, LTD., A DELAWARE CORPORATION; DOW PHARMACEUTICAL SCIENCES, INC., A DELAWARE CORPORATION; VALEANT PHARMACEUTICALS NORTH AMERICA LLC, A DELAWARE LLC; PRESTWICK PHARMACEUTICALS, INC., A DELAWARE CORPORATION; VALEANT BIOMEDICALS, INC., A DELAWARE CORPORATION
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 026606/0061 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2009
From: MADERNA, ANDREAS; VERNIER, JEAN-MICHEL; BARAKWAR, DINESH; CHAMAKURA, VARAPRASAD; EL ABDELLAOUI, HASSAN; HONG, ZHI
To: ARDEA BIOSCIENCES
Reel/Frame 022903/0991 →